Viatris Inc. (NASDAQ: VTRS) is a new kind of healthcare company, empowering people worldwide to live healthier at every stage of life. We provide access to medicines, advance sustainable operations, develop innovative solutions and leverage our collective expertise to connect more people to more products and services through our one-of-a-kind Global Healthcare Gateway^TM. Formed in November 2020 through the combination of Mylan and Upjohn, a legacy division of Pfizer, Viatris brings together scientific, manufacturing and distribution expertise with proven regulatory, medical and commercial capabilities to deliver high-quality medicines to patients in more than 165 countries and territories. Viatris’ portfolio comprises more than 1,400 approved molecules across a wide range of therapeutic areas, spanning both non-communicable and infectious diseases, including globally recognized brands, complex generic and branded medicines, a growing portfolio of biosimilars and a variety of over-the-counter consumer products*. Examples of our iconic brands registered in Gulf include Lipitor, Viagra, Elidel, Dymista, Celebrex, and Norvasc. Our high quality global manufacturing, scientific excellence and vast supply chain network mean we are uniquely positioned to improve access to medicine for patients worldwide. With a global workforce of approximately 45,000, Viatris is headquartered in the U.S. Learn more at viatris.com and investor.viatris.com, and connect with us on Twitter at @ViatrisInc, LinkedIn and YouTube.

*Brands availability in markets will be subject to country-specific registrations and regulations.